Status:
COMPLETED
Erythromycin in Septic Patients: Immunomodulatory Role and Clinical Impact
Lead Sponsor:
Tunis University
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In sepsis and septic shock, the host response is characterized by a complex of immune-inflammatory reactions; triggered and activated by microbial components. These reactions are controlled by a balan...
Detailed Description
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is considered as the main cause of death in critically ill patients ranging from 20 to 5...
Eligibility Criteria
Inclusion
- a patient in whom the diagnosis of sepsis or septic shock is diagnosed (According to the definitions updated by the sepsis 3 consensus in 2016)
Exclusion
- Macrolide use for another indication.
- Known allergy to macrolides.
- A corrected QT prolonged (\> 440 ms for man and 460 ms for woman) or taking drugs with an increased risk of QT prolongation.
- QT prolongation attributed to erythromycin
- Underlying dysimmunity (unbalanced diabetes, autoimmune disease, etc.)
- Pregnant or breastfeeding woman.
- Death or discharge while participating in the protocol (day 0 to day 6)
- Non-compliance with the protocol
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2023
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04665089
Start Date
January 1 2022
End Date
April 30 2023
Last Update
May 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
intensive care unit of the University Hospital Center La Rabta
Tunis, Tunisia, 1007